Mill, Christopher P. http://orcid.org/0000-0003-0957-6009
Fiskus, Warren http://orcid.org/0000-0002-7343-6214
Das, Kaberi http://orcid.org/0000-0003-4702-0386
Davis, John A.
Birdwell, Christine E.
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Daver, Naval http://orcid.org/0000-0001-7103-373X
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
McGeehan, Gerard M.
Ruan, Xinjia
Su, Xiaoping
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Kantarjian, Hagop
Bhalla, Kapil N. http://orcid.org/0000-0001-5209-5126
Article History
Received: 17 February 2023
Revised: 13 March 2023
Accepted: 16 March 2023
First Online: 28 March 2023
Competing interests
: Gerard M. McGeehan is an employee of Syndax Pharmaceuticals. Kapil N. Bhalla has received research funding from Iterion, Foghorn, and Nurix Pharmaceuticals, and he serves as a consultant for Iterion Therapeutics, none of which are directly related to the content of this paper. The authors declare no competing interest.